Steven Z Pavletic

List of Publications by Year
in descending order

276 papers	19,652 citations	26567 56 h-index	11899 134 g-index
280 all docs	280 docs citations	280 times ranked	12984 citing authors

#	Article	IF	Citations
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2005, 11, 945-956.	2.0	3,213
2	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.	2.0	2,636
3	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
4	T Cells Genetically Modified to Express an Antiâ€“B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 2267-2280.	0.8	570
5	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 2012, 119, 296-307.	0.6	559
6	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. Journal of Clinical Oncology, 2016, 34, 1112-1121.	0.8	513
7	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
8	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
9	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328
10	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood, 2011, 117, 4651-4657.	0.6	319
11	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 375-396.	2.0	316
12	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 1-17.	2.0	311
13	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 984-999.	2.0	293
14	EBMTâˆ’NIHâˆ’CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplantation, 2018, 53, 1401-1415.	1.3	243
15	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 589-603.	2.0	228
16	Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD. Biology of Blood and Marrow Transplantation, 2010, 16, 1611-1628.	2.0	226
17	High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood, 2003, 102, 2364-2372.	0.6	219
18	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	4.5	199

#	Article	IF	Citations
19	Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain, 2010, 133, 2852-2865.	3.7	189
20	Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2009, 302, 306.	3.8	186
21	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1167-1187.	2.0	182
22	Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantationâ€"An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2010, 16, S106-S114.	2.0	166
23	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505.	2.0	165
24	Fluticasone, Azithromycin, and Montelukast Treatment forÂNew-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 710-716.	2.0	151
25	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	0.6	147
26	Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood, 2003, 102, 802-809.	0.6	132
27	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
28	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 2011, 117, 6714-6720.	0.6	128
29	Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the Germanâ€"Austrianâ€"Swiss Consensus Conference on Clinical Practice in Chronic GVHD. Cornea, 2012, 31, 299-310.	0.9	128
30	Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. Journal of Rheumatology, 2004, 31, 482-8.	1.0	125
31	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 780-792.	2.0	124
32	Chronic graft versus host disease. Current Opinion in Hematology, 2006, 13, 426-435.	1.2	109
33	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1343-1359.	2.0	105
34	Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research. Journal of Clinical Oncology, 2005, 23, 5788-5794.	0.8	104
35	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 871-890.	2.0	101
36	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clinical Cancer Research, 2015, 21, 2020-2028.	3.2	98

#	Article	IF	Citations
37	Increased T-bet+ cytotoxic effectors and type I interferonâ€“mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood, 2009, 113, 3620-3630.	0.6	93
38	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
39	Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biology of Blood and Marrow Transplantation, 2003, 9, 583-591.	2.0	86
40	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
41	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
42	Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. American Journal of Hematology, 2005, 78, 265-274.	2.0	79
43	Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation. Biology of Blood and Marrow Transplantation, 2010, 16, 1362-1369.	2.0	79
44	National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis. Biology of Blood and Marrow Transplantation, 2013, 19, 632-639.	2.0	79
45	A survey of diagnosis, management, and grading of chronic GVHD. Biology of Blood and Marrow Transplantation, 2002, 8, 32-39.	2.0	78
46	Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells. Blood, 2004, 103, 3986-3988.	0.6	77
47	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica, 2012, 97, 451-458.	1.7	77
48	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 337-344.	2.0	76
49	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 545-557.	0.6	72
50	Vulvovaginal Chronic Graft-Versus-Host Disease With Allogeneic Hematopoietic Stem Cell Transplantation. Obstetrics and Gynecology, 2007, 110, 1041-1049.	1.2	71
51	Transplantationâ€™s Greatest Challenges: Advances in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 2-10.	2.0	68
52	Prior rituximab correlates with less acute graftâ€versusâ€host disease and better survival in Bâ€cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 2009, 145, 816-824.	1.2	66
53	Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4+ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 1150-1160.	2.0	65
54	Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program. Biology of Blood and Marrow Transplantation, 2007, 13, 844-852.	2.0	65

#	Article	IF	Citations
55	Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2007, 35, 184-192.	0.2	63
56	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
57	A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. Biology of Blood and Marrow Transplantation, 2011, 17, 1619-1629.	2.0	61
58	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	0.8	61
59	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 2071-2074.	0.5	58
60	Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Instituteâ€“Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Transplantation, 2005, 11, 862-870.	2.0	56
61	Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice. Biology of Blood and Marrow Transplantation, 2011, 17, 167-175.	2.0	54
62	Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2009, 15, 370-376.	2.0	53
63	Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 1083-1090.	2.0	53
64	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1341-1348.	2.0	52
65	2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the Series. Biology of Blood and Marrow Transplantation, 2015, 21, 387-388.	2.0	51
66	Assessment of Joint and Fascia Manifestations in Chronic Graftâ€Versusâ€Host Disease. Arthritis and Rheumatology, 2014, 66, 1044-1052.	2.9	50
67	Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. Journal of Immunology, 2016, 197, 3490-3503.	0.4	50
68	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 367-378.	2.0	50
69	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 6-9.	2.0	49
70	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica, 2011, 96, 1528-1535.	1.7	48
71	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 1746-1753.	2.0	48
72	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	1.3	48

#	Article	IF	Citations
73	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 1517-1524.	2.0	47
74	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
75	Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 360-366.	2.0	43
76	Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation with Oral Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2010, 16, 948-956.	2.0	43
77	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood, 2016, 127, 160-166.	0.6	43
78	Quantitative Salivary Proteomic Differences in Oral Chronic Graft-versus-Host Disease. Journal of Clinical Immunology, 2012, 32, 1390-1399.	2.0	42
79	Oral Complications of Chronic Graft-Versus-Host Disease. Journal of the National Cancer Institute Monographs, 2019, 2019, .	0.9	42
80	Fluorescencein situHybridization Detection of Cytogenetic Abnormalities in B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Leukemia and Lymphoma, 2004, 45, 1595-1603.	0.6	40
81	Clinical significance of autoantibodies in a large cohort of patients with chronic graftâ€versusâ€host disease defined by NIH criteria. American Journal of Hematology, 2015, 90, 114-119.	2.0	40
82	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1920-1927.	2.0	40
83	National Cancer Instituteâ€™s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2011, 17, 443-454.	2.0	39
84	Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation: Diagnosis, Monitoring, Prevention, and Treatment. Seminars in Hematology, 2012, 49, 15-24.	1.8	39
85	Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 543-547.	2.0	37
86	Localization of Sclerotic-type Chronic Graft-vs-Host Disease to Sites of Skin Injury. Archives of Dermatology, 2011, 147, 1081.	1.7	37
87	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood, 2017, 130, 2131-2145.	0.6	37
88	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
89	Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium. Biology of Blood and Marrow Transplantation, 2013, 19, 967-972.	2.0	34
90	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica, 2018, 103, 1915-1924.	1.7	34

#	Article	IF	Citations
91	Acupuncture Treatment for Persistent Hiccups in Patients with Cancer. Journal of Alternative and Complementary Medicine, 2010, 16, 811-816.	2.1	32
92	Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. Biology of Blood and Marrow Transplantation, 2019, 25, 577-586.	2.0	32
93	Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood, 2013, 121, 2864-2874.	0.6	31
94	Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-vs-Host Disease. JAMA Dermatology, 2015, 151, 23.	2.0	31
95	Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplantation, 2019, 54, 383-392.	1.3	30
96	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 2014, 99, 1618-1623.	1.7	29
97	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica, 2015, 100, 690-695.	1.7	29
98	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood, 2021, 137, 126-137.	0.6	29
99	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	0.6	29
100	Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects. Cancer Treatment Reviews, 2009, 35, 653-661.	3.4	28
101	Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseaseâ€"Is It Now Ready for PrimeÂTime?. Biology of Blood and Marrow Transplantation, 2012, 18, S177-S183.	2.0	28
102	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the Series. Biology of Blood and Marrow Transplantation, 2005, 11, 943-944.	2.0	27
103	Microchimerism in Salivary Glands after Blood- and Marrow-Derived Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 429-433.	2.0	27
104	The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. Haematologica, 2018, 103, 1698-1707.	1.7	24
105	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e46-e54.	2.0	24
106	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	0.6	24
107	T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial. Blood, 2016, 128, 999-999.	0.6	24
108	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. Biology of Blood and Marrow Transplantation, 2015, 21, 640-645.	2.0	23

#	Article	IF	Citations
109	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 1649-1655.	2.0	22
110	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. Biology of Blood and Marrow Transplantation, 2012, 18, 1446-1454.	2.0	22
111	Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 2017.	2.2	22
112	Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica, 2015, 100, 1228-1236.	1.7	21
113	High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croatian Medical Journal, 2016, 57, 229-238.	0.2	21
114	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	0.6	21
115	Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation. The Journal of Supportive Oncology, 2010, 8, 119-25.	2.3	21
116	CD56 ^{bright} natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica, 2017, 102, 1936-1946.	1.7	20
117	Amniotic membrane transplantationâ€"a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1466-1469.	1.3	20
118	The role of immune ablation and stem cell transplantation in severe SLE. Best Practice and Research in Clinical Rheumatology, 2005, 19, 839-858.	1.4	19
119	Target Populations in Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseasesâ€". A Workshop Accompanying: Cellular Therapy for Treatment of Autoimmune Diseases, Basic Science and Clinical Studies, Including New Developments in Hematopoietic and Mesenchymal Stem Cell Therapy11Sponsored by the Bernie Marcus Foundation and the City of Hope National Medical Center, in Collaboration with NIAID, NCI, EULAR, and EBMT; Newport Beach, California; October 7, 2005. Biology of Blood and Marrow Transplantation, 2006, 12, 688-690.	2.0	19
120	Assessment of ovarian function with anti-MÃ¼llerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant. Fertility and Sterility, 2009, 91, 1529-1532.	0.5	19
121	Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation1. Transplantation, 2003, 76, 877-881.	0.5	18
122	Magnetic Resonance Imaging in Sclerotic-Type Chronic Graft-vs-Host Disease. Archives of Dermatology, 2009, 145, 918-22.	1.7	18
123	Outcomes of Human Leukocyte Antigenâ€"Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2014, 20, 1390-1398.	2.0	18
124	Extracorporeal photopheresis as a therapy for autoimmune diseases. Journal of Clinical Apheresis, 2015, 30, 224-237.	0.7	18
125	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. JAMA Oncology, 2020, 6, 696.	3.4	18
126	Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation. Multiple Sclerosis Journal, 2004, 10, 284-289.	1.4	17

#	Article	IF	Citations
127	Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. British Journal of Haematology, 2004, 126, 837-843.	1.2	17
128	The Isomorphic Response in Morphealike Chronic Graft-vs-Host Disease. Archives of Dermatology, 2008, 144, 1229-31.	1.7	17
129	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. Biology of Blood and Marrow Transplantation, 2013, 19, 1102-1108.	2.0	17
130	Dose-Adjusted EPOCH-Rituximab Combined With Fludarabine Provides an Effective Bridge to Reduced-Intensity Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Lymphoid Malignancies. Journal of Clinical Oncology, 2012, 30, 830-836.	0.8	16
131	Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Experimental Hematology, 2013, 41, 772-778.	0.2	16
132	Characterization and Risk Factor Analysis of Osteoporosis inÂaÂLarge Cohort of Patients with Chronic Graft-versus-HostÂDisease. Biology of Blood and Marrow Transplantation, 2016, 22, 1517-1524.	2.0	16
133	Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma. American Journal of Hematology, 2004, 77, 31-35.	2.0	15
134	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1302-1308.	2.0	15
135	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	0.6	15
136	Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease. IScience, 2022, 25, 103592.	1.9	15
137	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	2.5	14
138	Rippled skin, fasciitis, and joint contractures. Journal of the American Academy of Dermatology, 2008, 59, 1070-1074.	0.6	13
139	Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease. Nature Clinical Practice Rheumatology, 2008, 4, 184-191.	3.2	12
140	Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. Bone Marrow Transplantation, 2019, 54, 76-84.	1.3	12
141	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Advances, 2020, 4, 40-46.	2.5	11
142	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host diseaseâ€"results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transplantation, 2021, 56, 243-256.	1.3	11
143	Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?. Croatian Medical Journal, 2016, 57, 6-15.	0.2	10
144	Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study. Bone Marrow Transplantation, 2021, 56, 1850-1858.	1.3	10

#	Article	IF	Citations
145	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Advances, 2021, 5, 2519-2522.	2.5	10
146	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. Blood, 2013, 122, 2093-2093.	0.6	10
147	Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatology, 2022, 61, 3317-3328.	0.9	10
148	Haematopoietic stem cell transplantation: indications, clinical developments and future directions. Expert Opinion on Pharmacotherapy, 2004, 5, 97-108.	0.9	9
149	Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease. Expert Opinion on Biological Therapy, 2007, 7, 1789-1797.	1.4	9
150	High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clinical Cancer Research, 2015, 21, 4312-4320.	3.2	9
151	CD69+ resident memory T cells are associated with graft-versus-host disease in intestinal transplantation. American Journal of Transplantation, 2021, 21, 1878-1892.	2.6	9
152	Strategies to Improve Long-Term Outcome in Stage IIIB Inflammatory Breast Cancer: Multimodality Treatment Including Dose-Intensive Induction and High-Dose Chemotherapy. Biology of Blood and Marrow Transplantation, 2009, 15, 963-970.	2.0	8
153	Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1415-1423.	2.0	8
154	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy. , 0, , 1304-1324.		8
155	High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. International Immunopharmacology, 2003, 3, 279-283.	1.7	7
156	Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters. Croatian Medical Journal, 2016, 57, 266-275.	0.2	7
157	Introduction to a review series on emerging immunotherapies for hematologic diseases. Blood, 2018, 131, 2617-2620.	0.6	7
158	Rehabilitation Interventions in the Multidisciplinary Management of Patients With Sclerotic Graft-Versus-Host Disease of the Skin and Fascia. Archives of Physical Medicine and Rehabilitation, 2021, 102, 776-788.	0.5	7
159	Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR. Blood, 2018, 132, 697-697.	0.6	7
160	Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 151-151.	0.6	7
161	Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma?. Current Hematologic Malignancy Reports, 2010, 5, 229-238.	1.2	6
162	Syk and tired of current chronic GVHD therapies. Blood, 2015, 125, 3974-3975.	0.6	6

#	Article	IF	Citations
163	Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1615-1622.	1.1	6
164	Early Diagnosis of Labial Fusion in Women After Allogeneic Hematopoietic Cell Transplant Enables Outpatient Treatment. Journal of Lower Genital Tract Disease, 2017, 21, 157-160.	0.9	6
165	Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 1980-1988.	2.0	6
166	Clinical characteristics and cytokine biomarkers in patients with chronic graftâ€vsâ€host disease persisting seven or more years after diagnosis. American Journal of Hematology, 2020, 95, 387-394.	2.0	6
167	Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate. Supportive Care in Cancer, 2020, 28, 3679-3689.	1.0	6
168	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biology of Blood and Marrow Transplantation, 2020, 26, e305-e308.	2.0	6
169	Treatment of High-Risk Chronic GVHD. Biology of Blood and Marrow Transplantation, 2008, 14, 1436-1437.	2.0	5
170	Host Lymphocyte Depletion as a Strategy to Facilitate Early Full Donor Chimerism after Reduced-Intensity Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1509-1513.	2.0	5
171	Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. JAMA Dermatology, 2020, 156, 814.	2.0	5
172	Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2967-2978.	1.2	5
173	Quality of Life in Patients With Skin of Color and Chronic Graft-vs-Host Disease. JAMA Dermatology, 2020, 156, 589.	2.0	5
174	Challenges in Conducting Studies in Chronic Graft-versus-Host Disease. Clinical Hematology International, 2019, 1, 36.	0.7	5
175	Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease. Best Practice and Research in Clinical Haematology, 2004, 17, 327-343.	0.7	4
176	Blood stem cells as therapy for severe lupus. Expert Opinion on Biological Therapy, 2005, 5, 1153-1164.	1.4	4
177	Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2016, 22, S50-S52.	2.0	4
178	Immunogenicity of HPV Quadrivalent Vaccine in Women after Allogeneic HCT is Comparable to Healthy Volunteers. Biology of Blood and Marrow Transplantation, 2018, 24, S85-S86.	2.0	4
179	Accompanying editorial on paper Neutrophil extracellular traps (NETs) contribute to Pathological Changes of ocular graft-vs.-Host Disease (oGVHD) dry eye: Implications for novel Biomarkers and Therapeutic Strategies by Seungwon An et al.. Ocular Surface, 2019, 17, 372-373.	2.2	4
180	B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease. Croatian Medical Journal, 2021, 62, 154-164.	0.2	4

#	Article	IF	Citations
181	Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 2934-2939.	1.3	4
182	Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd. Blood, 2019, 134, 874-874.	0.6	4
183	Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease. Blood, 2015, 126, 99-99.	0.6	4
184	Chronic graft-vs-host disease in 2016: a major challenge and an opportunity. Croatian Medical Journal, 2016, 57, 1-3.	0.2	3
185	Plasma Osteopontin Is a Biomarker Specifically Associated with Bronchiolitis Obliterans Syndrome after HCT. Biology of Blood and Marrow Transplantation, 2016, 22, S417-S418.	2.0	3
186	Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graftâ€versusâ€host disease. American Journal of Hematology, 2017, 92, E162-E164.	2.0	3
187	HPV32â€related Heckâ€™s disease in a chronic graftâ€versusâ€host disease patient with longâ€term successful KTP laser treatment: A rare case report. Clinical Case Reports (discontinued), 2021, 9, e04253.	0.2	3
188	Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).. Blood, 2006, 108, 317-317.	0.6	3
189	Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease. Blood, 2015, 126, 922-922.	0.6	3
190	NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 645-647.	2.3	3
191	â€œRegulatingâ€•rheumatoid arthritis via autotransplantation. Blood, 2008, 111, 4838-4839.	0.6	2
192	T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT. Biology of Blood and Marrow Transplantation, 2014, 20, S130-S131.	2.0	2
193	Predictive Models Using NIH Criteria and Clinical Characteristics Define Diagnosis, Disease Activity and Risk Factors for Chronic Ocular Graft-Versus Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S328.	2.0	2
194	Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?. Croatian Medical Journal, 2016, 57, 239-246.	0.2	2
195	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2007, 110, 1063-1063.	0.6	2
196	Elevated BAFF Is Correlated with Inflammatory Processes in Chronic Graft Versus Host Disease and Supports Increases in Transitional B Cells. Blood, 2008, 112, 465-465.	0.6	2
197	Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD).. Blood, 2009, 114, 3326-3326.	0.6	2
198	Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.. Blood, 2010, 116, 1245-1245.	0.6	2

#	Article	IF	Citations
199	Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS. Blood, 2012, 120, 1939-1939.	0.6	2
200	Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial. Blood, 2015, 126, 65-65.	0.6	2
201	Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion. Blood, 2012, 120, 1349-1349.	0.6	2
202	Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 198-201.	1.2	1
203	Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources. Biology of Blood and Marrow Transplantation, 2019, 25, S353-S354.	2.0	1
204	Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.. Blood, 2004, 104, 2751-2751.	0.6	1
205	The Balance of Effector and Regulatory Cell Populations in Oral Chronic GVHD: Potential Role of IL-15.. Blood, 2007, 110, 1059-1059.	0.6	1
206	Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.. Blood, 2007, 110, 167-167.	0.6	1
207	Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy. Blood, 2010, 116, 521-521.	0.6	1
208	Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes,. Blood, 2011, 118, 4074-4074.	0.6	1
209	Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2012, 120, 3054-3054.	0.6	1
210	Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation â€“ Results From The Prospective German Multicenter Validation Trial. Blood, 2013, 122, 2073-2073.	0.6	1
211	Development and Preliminary Testing Of The Post-Transplant Multimorbidity Index (PTMI). Blood, 2013, 122, 2076-2076.	0.6	1
212	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. Blood, 2013, 122, 3309-3309.	0.6	1
213	Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd. Blood, 2016, 128, 507-507.	0.6	1
214	All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients. Blood, 2016, 128, 669-669.	0.6	1
215	Identical-Twin Transplants for B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 3330-3330.	0.6	1
216	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. Blood, 2007, 110, 3049-3049.	0.6	1

#	Article	IF	Citations
217	Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309). Blood, 2019, 134, 3277-3277.	0.6	1
218	Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials. Blood, 2021, 138, 3898-3898.	0.6	1
219	Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. HemaSphere, 2022, 6, e730.	1.2	1
220	CD34-selected versus unmanipulated grafts for severe rheumatoid arthritis: Comment on the article by Moore et al. Arthritis and Rheumatism, 2003, 48, 1463-1464.	6.7	0
221	NHANES III Equations for PFT Interpretation Significantly Alter the Number of BOS Diagnoses After Hematopoietic Stem Cell Transplantation (HSCT). Chest, 2010, 138, 815A.	0.4	0
222	Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium. Biology of Blood and Marrow Transplantation, 2013, 19, S338.	2.0	0
223	Regulatory B Cells Deficiency in Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, S273.	2.0	0
224	Factors Associated with Fatigue in Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, S148.	2.0	0
225	Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD. Biology of Blood and Marrow Transplantation, 2015, 21, S59-S60.	2.0	0
226	Early Diagnosis of Labial Fusion Enables Medical Treatment in an Office Setting. Biology of Blood and Marrow Transplantation, 2015, 21, S184.	2.0	0
227	Autologous Rapamycin-Resistant T Cell Therapy of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, S65-S66.	2.0	0
228	Th17 Recruitment and Interferon Pathway Activation in Oral Chronic Graft-Versus-Host Disease Tissues. Biology of Blood and Marrow Transplantation, 2016, 22, S90-S91.	2.0	0
229	DLI Therapy Using T-Rapa Cells: Graft-Versus-Lymphoma and GvHD Effects. Biology of Blood and Marrow Transplantation, 2016, 22, S395-S396.	2.0	0
230	Predictors for Permanent Discontinuation of Systemic Immunosuppression in Patients with Moderate to Severe Chronic Graft-Versus-Host-Disease. Biology of Blood and Marrow Transplantation, 2016, 22, S49-S50.	2.0	0
231	Health Economics of Steroid Refractory Chronic Graft-Versus-Host-Disease Treatments: Cost-Utility Based Meta-Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, S379-S380.	2.0	0
232	Sarcopenia in cgvhd patients. Clinical Nutrition, 2018, 37, S116.	2.3	0
233	Cytomegalovirus (CMV) Infection and Disease Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation (HCT) Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation From a Single Institution. Biology of Blood and Marrow Transplantation, 2018, 24, S377-S378.	2.0	0
234	Chronic Graft-Versus-Host Disease Abrogates Standard Risk Factors for Malignancy Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S374.	2.0	0

#	Article	IF	Citations
235	Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 1584-1592.	1.3	0
236	Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkinâ€™s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 1643-1643.	0.6	0
237	Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy.. Blood, 2006, 108, 5333-5333.	0.6	0
238	Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.. Blood, 2007, 110, 1667-1667.	0.6	0
239	Risk Factors for Acute Graft-Versus-Host Disease (GvHD) after Related Donor HLA-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Adult Leukemia: Identification of Modifiable and Non-Modifiable Factors. A CIBMTR Study.. Blood, 2007, 110, 1069-1069.	0.6	0
240	Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa.. Blood, 2008, 112, 2231-2231.	0.6	0
241	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).. Blood, 2009, 114, 2256-2256.	0.6	0
242	Determinants of Platelet Counts in Patients with Chronic Graft Versus Host Disease.. Blood, 2009, 114, 2243-2243.	0.6	0
243	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. Blood, 2010, 116, 898-898.	0.6	0
244	Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium. Blood, 2010, 116, 220-220.	0.6	0
245	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors â€“ An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	0.6	0
246	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 211-211.	0.6	0
247	Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors. Blood, 2010, 116, 3530-3530.	0.6	0
248	Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium. Blood, 2010, 116, 393-393.	0.6	0
249	Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.. Blood, 2010, 116, 3476-3476.	0.6	0
250	Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.. Blood, 2010, 116, 3451-3451.	0.6	0
251	Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium. Blood, 2011, 118, 1988-1988.	0.6	0
252	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3094-3094.	0.6	0

#	Article	IF	Citations
253	Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism. Blood, 2011, 118, 1937-1937.	0.6	0
254	Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response. Blood, 2011, 118, 1978-1978.	0.6	0
255	Change in NIH Skin Score 0â€“3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium. Blood, 2011, 118, 151-151.	0.6	0
256	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	0.6	0
257	Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT. Blood, 2012, 120, 471-471.	0.6	0
258	Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 4201-4201.	0.6	0
259	Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion. Blood, 2013, 122, 4580-4580.	0.6	0
260	B Cell Deficiency and CD21low B Cells As Markers For Measuring Cgvhd Severity and Activity In a Large Patient Cohort. Blood, 2013, 122, 4623-4623.	0.6	0
261	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. Blood, 2013, 122, 4614-4614.	0.6	0
262	FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT. Blood, 2014, 124, 1147-1147.	0.6	0
263	Immunotherapy for acute leukemia. Aging, 2015, 7, 354-355.	1.4	0
264	A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Blood, 2015, 126, 64-64.	0.6	0
265	Implementation of NIH Criteria for Standardization of Chronic Graft-Versus-Host Disease in Croatia: Two-Year Experience. Blood, 2015, 126, 5580-5580.	0.6	0
266	Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party. Blood, 2015, 126, 3151-3151.	0.6	0
267	Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 1962-1962.	0.6	0
268	Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis. Blood, 2015, 126, 1937-1937.	0.6	0
269	Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD). Blood, 2015, 126, 145-145.	0.6	0
270	A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease. Blood, 2016, 128, 826-826.	0.6	0

#	Article	IF	Citations
271	Increased TLR7 Signaling of BCR-Activated B Cells in Chronic Graft-Versus Host Disease (cGVHD). Blood, 2017, 130, 75-75.	0.6	0
272	Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy. Blood, 2019, 134, 4558-4558.	0.6	0
273	Clinical Characterization and Cytokine Profile of Fatigue in Patients with Chronic Gvhd. Blood, 2019, 134, 3282-3282.	0.6	0
274	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2021, 138, 1815-1815.	0.6	0
275	A New Diagnostic Classification Tool for Pulmonary Chronic Graft-Versus-Host-Disease: Adaptation of the International Society for Heart and Lung Transplantation Chronic Lung Allograft Dysfunction Consensus Criteria. Blood, 2021, 138, 3919-3919.	0.6	0
276	Pleuroparenchymal Fibroelastosis in Patients with Chronic Graft-Versus-Host-Disease: A Rare Delayed Complication of Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, S396-S397.	0.6	0